Swollen Painful Joints in Active RA
Current Rheumatoid Arthritis Studies
- Do you have severe joint pain and swelling caused by RA?
- Do you take methotrexate for your RA?
- Do you take prednisone for your RA, but feel ready to try something different?
- Do you take Enbrel, Humira or Remicade for RA but want to explore research options?
You may wish to consider participating in a research study of an investigational drug for RA. (Investigational means that the study medication isn't yet approved for use by the general public.)
- Randomized Withdrawal of Etanercept or Methotrexate for Maintanence of Remission
Is your rheumatoid arthritis so well controlled with Enbrel & methotrexate you wonder if you still need to take them for your arthritis to remain fully controlled?
What should I do: continue with both, stop methotrexate or stop Enbrel?
The study has been designed to try to answer this practical question. The purpose of this study is to evaluate the efficacy of etanercept monotherapy compared to methotrexate monotherapy on maintenance of remission in subjects with Rheumatoid Arthritis who were on etanercept plus methotrexate therapy.
This is a multicenter, randomized withdrawl, double-blind controlled study in subjects with Rheumatoid Arthritis on etanercept plus methotrexate therapy who are in very good disease control for 6 months prior to study entry.
- Rituxumab Biosimilar Phase 3 Clinical Trial
This is a head to head comparison of Rituxan to a biologically similar Rituximab antibody intended to be a "generic" equivalent. Enrollment is completed.
- Adalimumab Biosimilar Phase 3 Clinical Trial
This is a head to head comparison of Humira to a biologically similar Adalimumab antibody intended to be a "generic" equivalent. Enrollment is completed.
- Baricitinib Phase 3 Clinical Trials
We are conducting four phase 3 clinical trials of baricitinib in patients with rheumatoid arthritis to evaluate its effectiveness in different stages of RA (recent onset or resistant to treatment). This once-a-day oral JAK 1,2 inhibitor is a promising candidate as it outperformed AbbVie’s Humira (adalimumab), the world top-selling pharmaceutical, in a head to head trial. Enrollment for all trials is closed. On Jan. 19, 2016 Eli Lilly and Company announced it had submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
Want to learn more?
We have only shared a brief overview of our current research projects. If you are interested in learning more about participation, please contact our research coordinator via email using the form below. She would be happy to provide further information on specific studies via email and follow up with you on the phone to answer your questions about the details of participation. You may also reach her by calling 616.459.8088.